The abstract is read at the publisher; the summary is JClub's.
In a retrospective cohort of 137 patients with metastatic pulmonary large cell neuroendocrine carcinoma, median overall survival was 10.0 months, with 16.3 months in transformed cases.
- Why it matters: Outcomes in metastatic LCNEC are poor and the disease is clinically and molecularly heterogeneous, leaving uncertainty about whether molecularly aligned standard regimens improve survival.
- What they did: The study compiled clinicopathologic, immunohistochemical, and genomic data, used curated pathology review for suspected transformed LCNEC, and estimated outcomes with Kaplan-Meier methods.
- The result: Among 115 with genomic data, survival was not statistically different with NSCLC-like versus SCLC-like regimens (12.1 vs 9.4 months) or with immunotherapy plus chemotherapy versus chemotherapy alone (9.9 vs 10.4 months).
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.